Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.

  title={Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.},
  author={Beatrice Mercorelli and David Lembo and Giorgio Pal{\`u} and Arianna Loregian},
  journal={Pharmacology & therapeutics},
  volume={131 3},
Human cytomegalovirus (HCMV) infection is associated with severe morbidity and mortality in immunocompromised individuals, mainly transplant recipients and AIDS patients, and is the most frequent cause of congenital malformations in newborn children. To date, few drugs are licensed for the treatment of HCMV infections, most of which target the viral DNA polymerase and suffer from many drawbacks, including long-term toxicity, low potency, and poor bioavailability. In addition, the emergence of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 19 extracted citations


Publications referenced by this paper.
Showing 1-10 of 289 references

Human cytomegalovirus resistance to antiviral drugs.

Antimicrobial agents and chemotherapy • 2005
View 11 Excerpts
Highly Influenced

Charge modification of plasma and milk proteins results in antiviral active compounds.

Journal of peptide science : an official publication of the European Peptide Society • 1999
View 20 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…